biotech

The manipulation and editing of DNA is a field of study which can be quite divisive in conversation. On the one hand, we are exploring new frontiers of scientific...

Horizon 3 Biotech is an AU$100m venture capital fund investing to improve lives globally through investments in public and private later-stage companies targeting a...

The reopening play has recently resurfaced as a popular theme amongst investors, with fund managers and punters alike looking through what we all hope to be the last...

We don’t know if CIO Matt McNamara actually Iikes saying ‘no’ quite as much as he has to, but the success of Horizon 3 Biotech depends on it. Of the three to five...

When is the perfect time to invest in a company, and how do you decide? Jumping in with an early-stage company that is burning with potential can bring enormous...

Biotech is a booming sector currently worth US$755 billion and forecast to be triple that by 2028. This is all very well but what exactly is Biotech? It's about genes,...

Australia's favourite long-term growth story and biotech darling CSL (ASX:CSL) has reported its full-year results, with net profit after tax up 10% to approximately...

The healthcare space stands out given it serves a noble cause: firms are looking to increase standards of living for people everywhere. Australia is fortunate to have...

Little is more exciting than a speccy healthcare stock (The possibility of rapid price appreciation is probably only rivalled only by a good mining micro-cap). As it...

Earlier in the year, we found that Australia's best performing sectors of the past decade were healthcare and technology. They are both fan favourites given their...

The IIR Pharma & Biotech Index increased slightly in March, up 1.3%. The index has performed strongly since the lows resulting from the pandemic, up 67.4% over the...

A look at the performance of the pharmaceutical and biotech sector over the month of February, along with the companies providing exposure to in vitro diagnostics....

Investing in biotech is often seen as binary: you either win big or lose everything. The success of CSL has been well chronicled, however, is it possible to...

Dr Craig Collie of Regal Funds Management joins David on this episode of Inside the Rope to discuss his career to date, starting as a medical doctor in...

Healthcare, like technology, is about innovation. In recent years, scientists have developed a range of new tools to treat a wide range of health problems. These can...

After extensive research (detailed below) we believe Invex Therapeutics (IXC AU) will pass its upcoming phase 2 trial in Idiopathic Intracranial Hypertension (IIH)...

The Nobel Prize in Medicine 2019 was awarded to three men for “their discoveries of how cells sense and adapt to oxygen availability”. The Nobel Prize in Medicine 2018...

Prior to the end of 2019, Fiftyone Capital shared an update with our investors in the Progressive Global Fund regarding our holding Paradigm Biopharmaceuticals...

Basil Fawlty famously sought to avoid mentioning the war, but opioid producer Palla Pharma (PAL, $1.03) won’t even try to downplay the tricky topic.The ‘war’ in this...

You rarely hear value investors espousing small-cap biotech stocks, given their typically binary outcomes make the risk profile totally unsuitable. However, what we...